Solanki Smit Bharat
Department of Obstetrics and Gynaecology, Institute of Kidney Diseases and Research Center, Dr. HL Trivedi Institute of Transplantation Sciences, Ahmedabad, Gujarat, India.
J Midlife Health. 2025 Apr-Jun;16(2):179-185. doi: 10.4103/jmh.jmh_34_25. Epub 2025 Jun 23.
Stress urinary incontinence (SUI) is a significant health concern among peri-and postmenopausal women, often leading to diminished quality of life. Transcutaneous temperature-controlled radiofrequency (TTCRF) has emerged as a minimally invasive treatment option, but its efficacy may be limited in cases of severe tissue laxity. Platelet-rich plasma (PRP) offers a promising adjunct to enhance tissue remodeling and functional recovery when combined with TTCRF.
This study evaluates the safety, efficacy, and patient-reported outcomes of combining PRP with TTCRF for treating SUI in peri- and postmenopausal women, aiming to address gaps in current therapeutic strategies.
A prospective, randomized controlled trial was conducted involving 80 peri- and postmenopausal women diagnosed with SUI. Participants were randomly assigned to two groups: PRP plus TTCRF (intervention group, = 40) and TTCRF alone (control group, = 40). Primary outcome measures included objective improvement assessed via urodynamic studies and subjective improvement evaluated using validated questionnaires (International Consultation on Incontinence Questionnaire - Short Form [ICIQ-SF] and Urogenital Distress Inventory). Secondary outcomes encompassed quality of life (Pelvic Floor Distress Inventory [PFDI-20]) and adverse event reporting. Statistical analyses were performed using SPSS version 27.0, with significance set at < 0.05.
At the 12-month follow-up, the intervention group demonstrated significantly superior outcomes compared to the control group. The mean reduction in ICIQ-SF scores was 9.8 points versus 6.6 points ( = 0.001), and urodynamic parameters improved by 32% more in the PRP plus TTCRF group ( = 0.003). Quality of life, as measured by PFDI-20, showed a 22% greater improvement in the intervention group ( = 0.002).
Combining PRP with TTCRF represents an innovative, minimally invasive approach that enhances tissue regeneration and functional recovery in peri- and post-menopausal women with SUI. These findings highlight the potential of PRP to augment the efficacy of TTCRF and warrant further investigation in larger, multicenter trials.
压力性尿失禁(SUI)是围绝经期和绝经后女性的一个重大健康问题,常导致生活质量下降。经皮温度控制射频(TTCRF)已成为一种微创治疗选择,但在严重组织松弛的情况下其疗效可能有限。富血小板血浆(PRP)与TTCRF联合使用时,为增强组织重塑和功能恢复提供了一种有前景的辅助方法。
本研究评估PRP与TTCRF联合治疗围绝经期和绝经后女性SUI的安全性、疗效及患者报告的结局,旨在填补当前治疗策略的空白。
进行了一项前瞻性随机对照试验,纳入80例诊断为SUI的围绝经期和绝经后女性。参与者被随机分为两组:PRP加TTCRF组(干预组,n = 40)和单纯TTCRF组(对照组,n = 40)。主要结局指标包括通过尿动力学研究评估的客观改善情况以及使用经过验证的问卷(国际尿失禁咨询问卷 - 简表[ICIQ - SF]和泌尿生殖系统困扰量表)评估的主观改善情况。次要结局包括生活质量(盆底困扰量表[PFDI - 20])和不良事件报告。使用SPSS 27.0版进行统计分析,显著性设定为P < 0.05。
在12个月的随访中,干预组的结局明显优于对照组。ICIQ - SF评分的平均降低值在干预组为9.8分,而在对照组为6.6分(P = 0.001),并且PRP加TTCRF组的尿动力学参数改善幅度多32%(P = 0.003)。以PFDI - 20衡量的生活质量在干预组改善幅度大22%(P = 0.002)。
PRP与TTCRF联合使用是一种创新的微创方法,可增强围绝经期和绝经后SUI女性的组织再生和功能恢复。这些发现凸显了PRP增强TTCRF疗效的潜力,值得在更大规模的多中心试验中进一步研究。